Mesalazine
Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory therapeutic agent used primarily in the management of inflammatory bowel diseases, especially ulcerative colitis.
Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory therapeutic agent used primarily in the management of inflammatory bowel diseases, especially ulcerative colitis. It acts locally within the intestinal lumen and colonic mucosa, where it helps suppress inflammatory signaling and reduce mucosal injury. In pharmaceutical development, mesalazine is notable for its high oral dose requirement and for the need to deliver the drug to the colon while minimizing premature release in the upper gastrointestinal tract.
From a formulation and biopharmaceutic perspective, mesalazine is a challenging active pharmaceutical ingredient because its therapeutic effect depends strongly on dissolution behavior, gastrointestinal pH, fluid volume, buffer capacity, transit time, and product design. Recent work has continued to examine how its physicochemical properties, including particle size, crystal habit, crystallinity, wetting, and packing, influence performance in oral and rectal dosage forms.
Where the papers sit
10 papers from the last 6 months study mesalazine directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 human data · 8 preclinical · 1 unclassified
Themes 3 themes
-
Ulcerative Colitis Maintenance Therapy
Ulcerative colitis maintenance is being shaped by treatment choice, adherence, and more precise colonic delivery. Clinical work compares switching among oral 5-aminosalicylic acid drugs and addresses corticosteroid use in older adults with mild-to-moderate disease. Colon-retentive microparticles and pH-sensitive linoleic acid nanocubosome pellets seek to improve local exposure. The shared aim is sustained remission with simpler, better-targeted therapy, although comparative clinical evidence remains limited.
4 papers · 40%
-
Mesalamine Release Engineering
Controlled oral release is the central goal, spanning delayed-release screening and sustained-release tablets. Bicarbonate dissolution testing is being developed to better predict formulation performance in vivo. Xanthan and tragacanth gums are used to extend release, while particle size and crystal habit are linked to packing, wetting, and dissolution. The work is moving toward formulation designs guided by biopredictive dissolution and drug-substance properties.
3 papers · 30%
-
Targeted Ulcerative Colitis Therapy
Ulcerative colitis treatment is moving toward localized delivery and pathway-directed anti-inflammatory effects. Thermo-responsive enema polymers and oral microparticles aim to concentrate therapy in the bowel while limiting systemic exposure. PI3K-Akt and NF-κB modulation recurs in mechanistic analyses, alongside evaluation of cobalt coordination microparticles and diosmin-related protection. Efficacy, tolerability, and the durability of these targeted approaches remain open questions.
3 papers · 30%
Papers
The 10 papers from the last 6 months that study mesalazine directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Ulcerative Colitis Maintenance Therapy (4)
- Clinical profiles and management strategies in older adults with mild-to-moderate ulcerative colitis: a multicenter, comparative, real-world study. Intestinal research · 11 Nov 2026 PMID 43010798
- Linoleic acid-based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis: in vitro and in vivo comparison with non-pH-sensitive and conventional formulations. Drug development and industrial pharmacy · 12 Aug 2026 PMID 42585548
- Switching from sulphasalazine or oral 5-aminosalicylic acid to another oral 5-aminosalicylic acid drug in the maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews · 27 Jul 2026 PMID 42504800
- Mesalamine colon-retentive microparticles for treatment of ulcerative colitis. International journal of pharmaceutics · 5 Jun 2026 PMID 42248222
Mesalamine Release Engineering (3)
- Development of discriminatory and biopredictive bicarbonate buffer-based dissolution method to screen delayed release formulations. Drug development and industrial pharmacy · 18 Aug 2026 PMID 42611030
- Development of sustained-release oral tablets using xanthan and tragacanth gums as release modifiers. International journal of pharmaceutics · 23 Jul 2026 PMID 42492645
- Understanding the Impact of Particle Size and Crystal Habit of Mesalamine Drug Substances on Their Packing, Wetting, and Dissolution Behaviour: A Science-based Approach for Selection of API Vendor. AAPS PharmSciTech · 27 May 2026 PMID 42204009
Targeted Ulcerative Colitis Therapy (3)
- Application of thermo-responsive polymers as an enema formulation for the treatment of ulcerative colitis. International journal of pharmaceutics · 14 Jul 2026 PMID 42447940
- Oral Cobalt Coordination Microparticles for Targeted Inflammatory Bowel Disease Treatment. ACS applied bio materials · 9 Jun 2026 PMID 42263142
- Integrated RNA-seq and network pharmacology analyses suggest PI3K-Akt and NF-κB pathway modulation in the protective effects of diosmin against experimental colitis. Food & function · 26 May 2026 PMID 42191164
By study type
Human data, design not indexed (1)
- Switching from sulphasalazine or oral 5-aminosalicylic acid to another oral 5-aminosalicylic acid drug in the maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews · 27 Jul 2026 PMID 42504800
Preclinical: animal, cell and lab studies (8)
- Development of discriminatory and biopredictive bicarbonate buffer-based dissolution method to screen delayed release formulations. Drug development and industrial pharmacy · 18 Aug 2026 PMID 42611030
- Linoleic acid-based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis: in vitro and in vivo comparison with non-pH-sensitive and conventional formulations. Drug development and industrial pharmacy · 12 Aug 2026 PMID 42585548
- Development of sustained-release oral tablets using xanthan and tragacanth gums as release modifiers. International journal of pharmaceutics · 23 Jul 2026 PMID 42492645
- Application of thermo-responsive polymers as an enema formulation for the treatment of ulcerative colitis. International journal of pharmaceutics · 14 Jul 2026 PMID 42447940
- Oral Cobalt Coordination Microparticles for Targeted Inflammatory Bowel Disease Treatment. ACS applied bio materials · 9 Jun 2026 PMID 42263142
- Mesalamine colon-retentive microparticles for treatment of ulcerative colitis. International journal of pharmaceutics · 5 Jun 2026 PMID 42248222
- Understanding the Impact of Particle Size and Crystal Habit of Mesalamine Drug Substances on Their Packing, Wetting, and Dissolution Behaviour: A Science-based Approach for Selection of API Vendor. AAPS PharmSciTech · 27 May 2026 PMID 42204009
- Integrated RNA-seq and network pharmacology analyses suggest PI3K-Akt and NF-κB pathway modulation in the protective effects of diosmin against experimental colitis. Food & function · 26 May 2026 PMID 42191164
Unclassified: not yet indexed with MeSH (1)
- Clinical profiles and management strategies in older adults with mild-to-moderate ulcerative colitis: a multicenter, comparative, real-world study. Intestinal research · 11 Nov 2026 PMID 43010798
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-26. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.